Clinical Trials

85 enrolled

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07105319 2025-08-22

ROPEG

65 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01735955 2024-02-08

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

GastrointestinalLymphoidMyeloidOther hematologic neoplasmSarcoma

57 enrolled 8 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Piebaldism, Gastrointestinal Stromal Tumors, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04155411 2022-07-27

Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

65 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02546674 2022-07-22

NILOdeepR

171 enrolled 23 charts

Phase 4 Not yet recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05367765 2022-05-10

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

2,400 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02602314 2022-01-20

SUSTRENIM

450 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02228382 2021-12-30

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

163 enrolled 27 charts

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00980018 2021-07-01

MACS0999

52 enrolled 14 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01243489 2019-12-20

Crescendo

104 enrolled

Patient Compliance, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01578213 2019-12-03

ISAV

112 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02204722 2018-06-15

IDEAL

55 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03216070 2017-07-13

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

12 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01605981 2017-04-20

MACS1881

Phase 4 Withdrawn

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02086487 2017-03-07

NISRI

98 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00171899 2017-02-23

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

80 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00786812 2017-02-23

MACS0439

89 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01368523 2016-11-16

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

19 enrolled

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00845221 2016-10-11

Glivec in Pediatric Chronic Myeloid Leukemia (CML)

44 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01043874 2016-04-08

MACS0911

45 enrolled 9 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01227577 2016-02-08

MACS1428

128 enrolled 11 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02389920 2015-03-17

Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

40 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02317159 2014-12-15

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

90 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01901666 2013-07-17

Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission

20 enrolled

Dwarfism, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00081926 2009-11-23

Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

112 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00461929 2009-02-13

GIST

68 enrolled

Chromosome Aberrations, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00390897 2008-11-27

Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia

360 enrolled